Table 3 Comorbid medical conditions in the prior 12-month period for patients initiating therapy with duloxetine versus venlafaxine XR.
From: Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
Condition | Duloxetine Group, % (n = 9,641) | Venlafaxine XR Group, % (n = 8,514) | p-value |
|---|---|---|---|
Other depressive disorder | 47.9 | 46.5 (NS) | .065 |
≥8 unique medical conditions | 38.6 | 29.1 | .0001 |
Pain | 76.3 | 67.8 | .0001 |
Muscle pain | 56.1 | 43.1 | .0001 |
Fibromyalgia | 17.4 | 9.5 | .0001 |
Back pain | 34.2 | 24.8 | .0001 |
Head pain | 25.3 | 21.1 | .0001 |
Chest pain | 20.0 | 16.5 | .0001 |
Neuropathic pain | 6.6 | 3.2 | .0001 |
Irritable bowel syndrome | 5.2 | 3.9 | .0001 |
Other pain | 27.1 | 23.2 | .0001 |
Dyslipidemia | 30.1 | 25.3 | .0001 |
Hypertension | 28.9 | 23.2 | .0001 |
Anxiety disorders | 25.6 | 24.6 (NS) | .145 |
GAD | 13.6 | 12.7 (NS) | .054 |
Panic anxiety | 6.15 | 5.93 (NS) | .536 |
PTSD | 5.02 | 4.36 (NS) | .035 |
Social anxiety | 1.11 | 1.46 (NS) | .037 |
Other anxiety | 6.05 | 5.95 (NS) | .794 |
Sleep disorder | 21.2 | 16.8 | .0001 |
Gastrointestinal | 20.4 | 16.8 | .0001 |
Nondependence drug abuse | 12.4 | 12.7 (NS) | .439 |
Diabetes mellitus | 11.5 | 8.6 | .0001 |
Bipolar disorder | 11.1 | 9.3 | .0001 |
Asthma | 10.1 | 8.9 (NS) | .006 |
Heart disease | 6.0 | 4.7 | .0001 |
Organic psychosis | 5.9 | 4.4 | .0001 |
ADHD | 5.4 | 4.4 (NS) | .003 |
Drug dependence | 5.5 | 4.4 | .0006 |
Alcohol dependence | 4.8 | 4.9 (NS) | .668 |
Diabetic neuropathy | 2.0 | 1.3 | .001 |
Schizophrenia | 1.2 | 1.3 (NS) | .744 |